Skip to main content

Celanese Corporation Reports Full Year 2025 and Fourth Quarter Earnings

Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported full year 2025 U.S. GAAP diluted loss per share of $10.44 and adjusted earnings per share of $3.98. The Company generated net sales of $9.5 billion in 2025, a 7 percent decrease from the previous year consisting of a 4 percent decline in price and a 4 percent decline in volume, with a small currency benefit. Throughout the year, the Company experienced lower-than-normal demand levels in key end-markets like automotive, paints, coatings, and construction. Celanese remained focused on the strategic priorities of increasing cash flow to accelerate deleveraging, intensifying cost improvements, and driving top line growth. The Company reported 2025 consolidated operating loss of $786 million, adjusted EBIT of $1.2 billion, and operating EBITDA of $1.9 billion at margins of (8), 12, and 20 percent, respectively. The Company also generated operating cash flow of $1.1 billion and free cash flow of $773 million.

The difference between U.S. GAAP diluted earnings per share and adjusted earnings per share in 2025 was primarily due to Certain Items totaling $1.6 billion1.

Celanese also reported fourth quarter 2025 U.S. GAAP diluted earnings per share of $0.23 and adjusted earnings per share of $0.67. The Company generated net sales of $2.2 billion in the fourth quarter, a sequential 9 percent decline driven by decreases of 7 percent in volume and 2 percent in price. Celanese reported fourth quarter consolidated operating profit of $93 million, adjusted EBIT of $251 million, and operating EBITDA of $435 million at margins of 4, 11, and 20 percent, respectively. These results were driven by greater than anticipated year-end destocking and competitive dynamics in acetate tow, with offsets from cost reductions in the quarter and mix improvement in Engineered Materials. The Company also reported operating cash flow of $252 million and free cash flow of $160 million in the quarter.

"Our full‑year performance demonstrates the strength of our action plans and disciplined execution in a challenging environment," said Scott Richardson, president and chief executive officer. "With over $770 million of free cash flow generation, over $120 million in cost reductions, the Micromax® divestiture completed, near-term maturities refinanced, and programs in place to drive growth and enrich our EM pipeline, we've made considerable progress against our priorities of deleveraging, cost improvement, and top‑line growth. While fourth‑quarter results reflected anticipated seasonality and softer volumes, the decisive steps we took throughout 2025—portfolio actions, cost reductions, footprint optimization, and prudent refinancing—position us well for continued improvement."

____________________

1

Primarily related to impairment of goodwill and certain trade names arising from our annual goodwill and indefinite-lived intangible assets impairment tests.

Fourth Quarter 2025 Financial Highlights:

 

Three Months Ended

 

December 31,
2025

 

September 30,
2025

 

December 31,
2024

 

(unaudited)

 

(In $ millions, except per share data)

Net Sales

 

 

 

 

 

Engineered Materials

 

1,277

 

 

 

1,384

 

 

 

1,269

 

Acetyl Chain

 

940

 

 

 

1,061

 

 

 

1,110

 

Intersegment Eliminations

 

(13

)

 

 

(26

)

 

 

(21

)

Total

 

2,204

 

 

 

2,419

 

 

 

2,358

 

 

 

 

 

 

 

Operating Profit (Loss)

 

 

 

 

 

Engineered Materials

 

111

 

 

 

(1,327

)

 

 

(1,521

)

Acetyl Chain

 

90

 

 

 

135

 

 

 

215

 

Other Activities

 

(108

)

 

 

(83

)

 

 

(113

)

Total

 

93

 

 

 

(1,275

)

 

 

(1,419

)

 

 

 

 

 

 

Net Earnings (Loss)

 

22

 

 

 

(1,353

)

 

 

(1,922

)

 

 

 

 

 

 

Adjusted EBIT(1)

 

 

 

 

 

Engineered Materials

 

183

 

 

 

200

 

 

 

143

 

Acetyl Chain

 

146

 

 

 

187

 

 

 

252

 

Other Activities

 

(78

)

 

 

(61

)

 

 

(76

)

Total

 

251

 

 

 

326

 

 

 

319

 

 

 

 

 

 

 

Equity Earnings and Dividend Income, Other Income (Expense)

 

 

 

 

 

Engineered Materials

 

32

 

 

 

35

 

 

 

33

 

Acetyl Chain

 

42

 

 

 

44

 

 

 

35

 

 

 

 

 

 

 

Operating EBITDA(1)

 

435

 

 

 

517

 

 

 

503

 

Diluted EPS - continuing operations

$

0.23

 

 

$

(12.39

)

 

$

(17.55

)

Diluted EPS - total

$

0.17

 

 

$

(12.39

)

 

$

(17.60

)

Adjusted EPS(1)

$

0.67

 

 

$

1.34

 

 

$

1.33

 

 

 

 

 

 

 

Net cash provided by (used in) investing activities

 

(104

)

 

 

(59

)

 

 

(128

)

Net cash provided by (used in) financing activities

 

(324

)

 

 

(118

)

 

 

(189

)

Net cash provided by (used in) operating activities

 

252

 

 

 

447

 

 

 

494

 

Free cash flow(1)

 

160

 

 

 

375

 

 

 

381

 

____________________

(1)

See "Non-US GAAP Financial Measures" below.

 

Year Ended December 31,

 

2025

 

2024

 

(unaudited)

 

(In $ millions, except per share data)

Net Sales

 

 

 

Engineered Materials

 

5,390

 

 

 

5,595

 

Acetyl Chain

 

4,232

 

 

 

4,763

 

Intersegment Eliminations

 

(78

)

 

 

(90

)

Total

 

9,544

 

 

 

10,268

 

 

 

 

 

Operating Profit (Loss)

 

 

 

Engineered Materials

 

(958

)

 

 

(1,197

)

Acetyl Chain

 

539

 

 

 

946

 

Other Activities

 

(367

)

 

 

(469

)

Total

 

(786

)

 

 

(720

)

 

 

 

 

Net Earnings (Loss)

 

(1,151

)

 

 

(1,534

)

 

 

 

 

Adjusted EBIT(1)

 

 

 

Engineered Materials

 

720

 

 

 

841

 

Acetyl Chain

 

695

 

 

 

1,097

 

Other Activities

 

(265

)

 

 

(313

)

Total

 

1,150

 

 

 

1,625

 

 

 

 

 

Equity Earnings and Dividend Income, Other Income (Expense)

 

 

 

Engineered Materials

 

109

 

 

 

178

 

Acetyl Chain

 

132

 

 

 

138

 

 

 

 

 

Operating EBITDA(1)

 

1,893

 

 

 

2,353

 

Diluted EPS - continuing operations

$

(10.44

)

 

$

(14.04

)

Diluted EPS - total

$

(10.64

)

 

$

(14.11

)

Adjusted EPS(1)

$

3.98

 

 

$

8.18

 

 

 

 

 

Net cash provided by (used in) investing activities

 

(349

)

 

 

(470

)

Net cash provided by (used in) financing activities

 

(513

)

 

 

(1,313

)

Net cash provided by (used in) operating activities

 

1,146

 

 

 

966

 

Free cash flow(1)

 

773

 

 

 

498

____________________

(1)

See "Non-US GAAP Financial Measures" below.

Fourth Quarter Business Segment Overview

Engineered Materials

Engineered Materials reported full year net sales of $5.4 billion, a 4 percent decrease compared to the previous year, driven by a 4 percent decrease in volume and a 1 percent decrease in price, with a small currency benefit. Engineered Materials launched a complexity reduction program early in 2025 to reduce costs and lower inventories. The business realized approximately $70 million in cost savings through the year, while reducing inventory by over $100 million. Engineered Materials reported full year operating loss of $958 million, adjusted EBIT of $720 million, and operating EBITDA of $1.2 billion, with margins of (18), 13, and 22 percent, respectively. Following substantial first quarter European automotive destocking, these initiatives largely steadied the business through the year despite continual volume headwinds.

Engineered Materials focused on continued improvement in pipeline quality and velocity to fully leverage the business's broad specialty products portfolio, deep material science application development expertise, and industry-leading capabilities in design and prototyping, computer aided engineering (CAE) simulation, and material processing. Also in 2025, Engineered Materials continued to advance commercial capabilities through the launch of AskChemille.com, a digital assistant platform for advanced material selection offering a comprehensive range of engineered material options.

Engineered Materials reported fourth quarter net sales of $1.3 billion, representing a decrease of 8 percent compared to the previous quarter, consisting of a 6 percent decrease in volume and 2 percent decrease in price. Volumes were pressured by channel partner destocking in the western hemisphere and lower than expected demand in Asia. The business reported fourth quarter operating profit of $111 million, adjusted EBIT of $183 million, and operating EBITDA of $288 million, with margins of 9, 14, and 23 percent, respectively. The results were driven by the business's efforts to reduce costs and drive mix enrichment, despite volume headwinds.

Acetyl Chain

The Acetyl Chain reported full year net sales of $4.2 billion, an 11 percent decrease compared to the previous year driven by a 6 percent decrease in volume and a 6 percent decrease in price, with a small currency benefit. Persistently weak demand in key end-markets like paints, coatings, and construction impacted the vinyls business in the western hemisphere. Additionally, in acetate tow, elevated competitive pressures and weaker demand conditions challenged volumes, pricing, and sales mix. The Acetyl Chain responded by exercising the agility and optionality that has become the hallmark of the business, and drove continuous actions to maximize earnings. The business reported full year operating profit of $539 million, adjusted EBIT of $695 million, and operating EBITDA of $947 million with margins of 13, 16, and 22 percent, respectively. The Acetyl Chain took significant steps to improve the near-term and longer-term performance of the business, including:

  • Announcing the intention to close the acetate tow manufacturing site in Lanaken, Belgium.
  • Idling the VAM facility in Frankfurt, Germany for most of the second half of the year.
  • Prioritizing production at the lowest-cost gulf coast sites to drive profitability and reduce cost-to-serve.
  • Driving growth in differentiated downstream applications to improve margins by leveraging the business's optionality.
  • Accelerating commercialization of Eco-CC sustainable products, especially in coatings and adhesives, to increase differentiation and grow share of downstream applications.
  • Accelerating deployment of manufacturing digitization tools throughout the Acetyl Chain production network.

The Acetyl Chain delivered fourth quarter net sales of $940 million, representing a sequential decrease of 11 percent, consisting of declines of 10 percent in volume and 1 percent in price. The overall demand environment remained challenged, with year-end seasonal declines greater than expected, especially in December. The Acetyl Chain delivered fourth quarter operating profit of $90 million, adjusted EBIT of $146 million, and operating EBITDA of $210 million at margins of 10, 16, and 22 percent, respectively. Utilizing the daily operating model, the business continued to take multiple actions to drive consistency of earnings. These included optimizing production at low-cost, U.S.-based sites, reducing operating rates at higher cost sites, and reducing global distribution costs to align with the demand environment.

Cash Flow and Tax

Celanese reported full year operating cash flow of $1.1 billion and free cash flow of $773 million. Full year 2025 operating cash flow and free cash flow results were mainly driven by cost reductions, disciplined management of capital expenditures, continued execution of the inventory reduction goals in Engineered Materials, and timing of working capital.

The effective U.S. GAAP income tax rate for the full year ended December 31, 2025 was 7 percent on a loss for the full year 2025, primarily driven by a book goodwill impairment charge of $1.1 billion for the Engineered Materials reporting unit that did not provide a tax benefit and an increase in valuation allowance on U.S. foreign tax credit carryforward due to the revised forecasts of foreign-source income. These impacts were partially offset by deferred tax benefits related to integration transactions and realignment of intangibles and tax benefits related to the resolution of tax examinations.

The effective tax rate for 2025 adjusted earnings was 8 percent excluding the impact of the goodwill charge that is non-deductible for tax purposes and other non-recurring items.

"Looking to the first quarter, we expect little change to the overall demand environment. We expect to see some modest seasonal improvements in volumes, and continued benefits from our cost reduction initiatives. These will be partially offset by the timing of the acetate tow dividend from our joint venture in China, which will be paid three times a year starting in the second quarter, similar to last year," continued Richardson. "Given this backdrop, we anticipate first quarter adjusted earnings per share to be $0.70 to $0.85."

"As we enter 2026, we remain focused on driving further cash generation, capturing additional cost savings, and advancing growth initiatives, to enhance long‑term value creation. We expect to have another strong year of cash generation with a targeted free cash flow of $650 to $750 million. Although the macro environment remains uncertain, we've created forward momentum. We believe the decisive actions we are taking position Celanese to meaningfully benefit from the eventual recovery."

Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT, operating EBITDA or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.

The Company's prepared remarks related to the fourth quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on February 17, 2026. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.

Celanese Corporation is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs more than 11,000 employees worldwide with 2025 net sales of $9.5 billion.

Forward-Looking Statements

This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, deleveraging efforts, planned cost reductions, dividend policy, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: the ability to successfully achieve planned cost reductions; changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, textiles, electronics and construction industries; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine, Polyamide 66 ("PA66"), polybutylene terephthalate, ethanol, natural gas and fuel oil, and the prices for electricity and other energy sources; the ability to pass increases in raw materials prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the possibility that we will not be able to realize the anticipated benefits of the Mobility & Materials business (the "M&M Business") we acquired from DuPont de Nemours, Inc. (the "M&M Acquisition"), including synergies and growth opportunities, whether as a result of difficulties arising from the operation of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; additional impairments of goodwill or intangible assets; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; risks and costs associated with increased leverage from the M&M Acquisition, including increased interest expense and potential reduction of business and strategic flexibility; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, terrorism or political unrest, public health crises, or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the direct or indirect consequences of acts of war or conflict (such as the Russia-Ukraine conflict or conflicts in the Middle East) or terrorist incidents or as a result of weather, natural disasters, or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties and trade agreements, tax rates or legislation throughout the world including, but not limited to, anti-dumping and countervailing duties, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities, in the countries in which we operate; our level of indebtedness, which could diminish our ability to raise additional capital to fund operations or limit our ability to react to changes in the economy or the chemicals industry, and the success of our deleveraging efforts, as well as any changes to our credit ratings; changes in currency exchange rates and interest rates; tax rates and changes thereto; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Non-GAAP Financial Measures

Presentation

This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.

Use of Non-US GAAP Financial Information

This release uses the following Non-US GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, adjusted earnings per share and free cash flow. These measures are not recognized in accordance with US GAAP and should not be viewed as an alternative to US GAAP measures of performance or liquidity. The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin is operating margin; for operating EBITDA margin is operating margin; for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; and for free cash flow is net cash provided by (used in) operations.

Definitions of Non-US GAAP Financial Measures

  • Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8 of our Non-US GAAP Financial Measures and Supplemental Information document). We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales.
  • Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We do not provide reconciliations for operating EBITDA on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales.
  • Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.

Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a of our Non-US GAAP Financial Measures and Supplemental Information document summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.

  • Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our noncontrolling interest joint ventures. We do not provide reconciliations for free cash flow on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.

Reconciliation of Non-US GAAP Financial Measures

Reconciliations of the Non-US GAAP financial measures used in this press release to the comparable US GAAP financial measure, together with information about the purposes and uses of Non-US GAAP financial measures, are included in our Non-US GAAP Financial Measures and Supplemental Information document filed as an exhibit to our Current Report on Form 8-K filed with the SEC on or about February 17, 2026 and also available on our website at investors.celanese.com under Financial Information/Financial Document Library.

Results Unaudited

The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Annual Report on Form 10-K for the annual period ending December 31, 2025.

Supplemental Information

Additional information about our prior period performance is included in our Quarterly Reports on Form 10-Q and in our Non-US GAAP Financial Measures and Supplemental Information document.

 

Consolidated Statements of Operations - Unaudited

 

Three Months Ended

 

December 31,
2025

 

September 30,
2025

 

December 31,
2024

 

(In $ millions, except share and per share data)

Net sales

2,204

 

 

2,419

 

 

2,358

 

Cost of sales

(1,781

)

 

(1,898

)

 

(1,832

)

Gross profit

423

 

 

521

 

 

526

 

Selling, general and administrative expenses

(223

)

 

(231

)

 

(263

)

Amortization of intangible assets

(40

)

 

(42

)

 

(40

)

Research and development expenses

(32

)

 

(31

)

 

(31

)

Other (charges) gains, net

(39

)

 

(1,491

)

 

(1,621

)

Foreign exchange gain (loss), net

7

 

 

2

 

 

12

 

Gain (loss) on disposition of businesses and assets, net

(3

)

 

(3

)

 

(2

)

Operating profit (loss)

93

 

 

(1,275

)

 

(1,419

)

Equity in net earnings (loss) of affiliates

37

 

 

39

 

 

39

 

Non-operating pension and other postretirement employee benefit (expense) income

50

 

 

2

 

 

(27

)

Interest expense

(177

)

 

(177

)

 

(164

)

Interest income

6

 

 

7

 

 

5

 

Dividend income - equity investments

40

 

 

40

 

 

33

 

Other income (expense), net

 

 

4

 

 

 

Earnings (loss) from continuing operations before tax

13

 

 

(1,360

)

 

(1,533

)

Income tax (provision) benefit

15

 

 

7

 

 

(384

)

Earnings (loss) from continuing operations

28

 

 

(1,353

)

 

(1,917

)

Earnings (loss) from operation of discontinued operations

(8

)

 

 

 

(6

)

Income tax (provision) benefit from discontinued operations

2

 

 

 

 

1

 

Earnings (loss) from discontinued operations

(6

)

 

 

 

(5

)

Net earnings (loss)

22

 

 

(1,353

)

 

(1,922

)

Net (earnings) loss attributable to noncontrolling interests

(3

)

 

(4

)

 

(3

)

Net earnings (loss) attributable to Celanese Corporation

19

 

 

(1,357

)

 

(1,925

)

Amounts attributable to Celanese Corporation

 

 

 

 

 

Earnings (loss) from continuing operations

25

 

 

(1,357

)

 

(1,920

)

Earnings (loss) from discontinued operations

(6

)

 

 

 

(5

)

Net earnings (loss)

19

 

 

(1,357

)

 

(1,925

)

Earnings (loss) per common share - basic

 

 

 

 

 

Continuing operations

0.23

 

 

(12.39

)

 

(17.55

)

Discontinued operations

(0.06

)

 

 

 

(0.05

)

Net earnings (loss) - basic

0.17

 

 

(12.39

)

 

(17.60

)

Earnings (loss) per common share - diluted

 

 

 

 

 

Continuing operations

0.23

 

 

(12.39

)

 

(17.55

)

Discontinued operations

(0.06

)

 

 

 

(0.05

)

Net earnings (loss) - diluted

0.17

 

 

(12.39

)

 

(17.60

)

Weighted average shares (in millions)

 

 

 

 

 

Basic

109.6

 

 

109.6

 

 

109.4

 

Diluted

109.8

 

 

109.6

 

 

109.4

 

Consolidated Statements of Operations - Unaudited

 

Year Ended December 31,

 

2025

 

2024

 

(In $ millions, except share and per share data)

Net sales

9,544

 

 

10,268

 

Cost of sales

(7,592

)

 

(7,932

)

Gross profit

1,952

 

 

2,336

 

Selling, general and administrative expenses

(899

)

 

(1,033

)

Amortization of intangible assets

(164

)

 

(159

)

Research and development expenses

(125

)

 

(130

)

Other (charges) gains, net

(1,581

)

 

(1,744

)

Foreign exchange gain (loss), net

36

 

 

24

 

Gain (loss) on disposition of businesses and assets, net

(5

)

 

(14

)

Operating profit (loss)

(786

)

 

(720

)

Equity in net earnings (loss) of affiliates

127

 

 

196

 

Non-operating pension and other postretirement employee benefit (expense) income

55

 

 

(20

)

Interest expense

(701

)

 

(676

)

Refinancing expense

(68

)

 

 

Interest income

24

 

 

33

 

Dividend income - equity investments

122

 

 

128

 

Other income (expense), net

7

 

 

40

 

Earnings (loss) from continuing operations before tax

(1,220

)

 

(1,019

)

Income tax (provision) benefit

90

 

 

(507

)

Earnings (loss) from continuing operations

(1,130

)

 

(1,526

)

Earnings (loss) from operation of discontinued operations

(24

)

 

(10

)

Income tax (provision) benefit from discontinued operations

3

 

 

2

 

Earnings (loss) from discontinued operations

(21

)

 

(8

)

Net earnings (loss)

(1,151

)

 

(1,534

)

Net (earnings) loss attributable to noncontrolling interests

(14

)

 

(8

)

Net earnings (loss) attributable to Celanese Corporation

(1,165

)

 

(1,542

)

Amounts attributable to Celanese Corporation

 

 

 

Earnings (loss) from continuing operations

(1,144

)

 

(1,534

)

Earnings (loss) from discontinued operations

(21

)

 

(8

)

Net earnings (loss)

(1,165

)

 

(1,542

)

Earnings (loss) per common share - basic

 

 

 

Continuing operations

(10.44

)

 

(14.04

)

Discontinued operations

(0.20

)

 

(0.07

)

Net earnings (loss) - basic

(10.64

)

 

(14.11

)

Earnings (loss) per common share - diluted

 

 

 

Continuing operations

(10.44

)

 

(14.04

)

Discontinued operations

(0.20

)

 

(0.07

)

Net earnings (loss) - diluted

(10.64

)

 

(14.11

)

Weighted average shares (in millions)

 

 

 

Basic

109.5

 

 

109.3

 

Diluted

109.5

 

 

109.3

 

Consolidated Balance Sheets - Unaudited

 

As of

December 31,

2025

 

As of

December 31,

2024

 

 

(In $ millions)

ASSETS

 

 

 

Current Assets

 

 

 

Cash and cash equivalents

1,263

 

 

962

 

Trade receivables - third party and affiliates, net

922

 

 

1,121

 

Non-trade receivables, net

545

 

 

493

 

Inventories

2,220

 

 

2,284

 

Assets held for sale

492

 

 

 

Other assets

251

 

 

266

 

Total current assets

5,693

 

 

5,126

 

Investments in affiliates

1,252

 

 

1,217

 

Property, plant and equipment, net

5,076

 

 

5,273

 

Operating lease right-of-use assets

359

 

 

388

 

Deferred income taxes

1,359

 

 

1,251

 

Other assets

601

 

 

555

 

Goodwill

4,171

 

 

5,387

 

Intangible assets, net

3,184

 

 

3,641

 

Total assets

21,695

 

 

22,838

 

LIABILITIES AND EQUITY

 

 

 

Current Liabilities

 

 

 

Short-term borrowings and current installments of long-term debt - third party and affiliates

1,204

 

 

1,501

 

Trade payables - third party and affiliates

1,279

 

 

1,228

 

Liabilities held for sale

75

 

 

 

Other liabilities

1,049

 

 

1,157

 

Income taxes payable

76

 

 

4

 

Total current liabilities

3,683

 

 

3,890

 

Long-term debt, net of unamortized deferred financing costs

11,394

 

 

11,078

 

Deferred income taxes

512

 

 

923

 

Uncertain tax positions

208

 

 

286

 

Benefit obligations

344

 

 

396

 

Operating lease liabilities

265

 

 

294

 

Other liabilities

817

 

 

408

 

Commitments and Contingencies

 

 

 

Shareholders' Equity

 

 

 

Treasury stock, at cost

(5,482

)

 

(5,486

)

Additional paid-in capital

431

 

 

409

 

Retained earnings

9,876

 

 

11,054

 

Accumulated other comprehensive income (loss), net

(776

)

 

(848

)

Total Celanese Corporation shareholders' equity

4,049

 

 

5,129

 

Noncontrolling interests

423

 

 

434

 

Total equity

4,472

 

 

5,563

 

Total liabilities and equity

21,695

 

 

22,838

 

Non-U.S. GAAP Financial Measures and Supplemental Information

February 17, 2026

In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.

Purpose

The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-U.S. GAAP financial measures. This document is updated quarterly.

Presentation

This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.

Use of Non-U.S. GAAP Financial Measures

From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with U.S. GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable U.S. GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.

Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other U.S. GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.

Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.

This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.

Specific Measures Used

This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with U.S. GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity.

Definitions

  • Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as adjusted EBIT.
  • Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. We do not provide reconciliations for operating EBITDA on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as operating EBITDA.
  • Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as operating profit (loss) attributable to Celanese Corporation.
  • Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.

    Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
  • Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures. We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations. Free cash flow is not a measure of cash available for discretionary expenditures since the Company has certain debt service and finance lease payments that are not deducted from that measure. We do not provide reconciliations for free cash flow on a forward-looking basis when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
  • Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.
  • Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our shareholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.

Supplemental Information

Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:

  • Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.
  • Cash dividends received from our equity investments.
  • For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside shareholders' interests are shown as NCI. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.

Results Unaudited

The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Annual Report on Form 10-K for the annual period ending December 31, 2025.

Table 1

Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions)

Net earnings (loss) attributable to Celanese Corporation

(1,165

)

 

19

 

 

(1,357

)

 

197

 

 

(24

)

 

(1,542

)

 

(1,925

)

 

113

 

 

152

 

 

118

 

(Earnings) loss from discontinued operations

21

 

 

6

 

 

 

 

10

 

 

5

 

 

8

 

 

5

 

 

2

 

 

1

 

 

 

Interest income

(24

)

 

(6

)

 

(7

)

 

(7

)

 

(4

)

 

(33

)

 

(5

)

 

(5

)

 

(10

)

 

(13

)

Interest expense

701

 

 

177

 

 

177

 

 

177

 

 

170

 

 

676

 

 

164

 

 

169

 

 

174

 

 

169

 

Refinancing expense

68

 

 

36

 

 

 

 

 

 

32

 

 

 

 

 

 

 

 

 

 

 

Income tax provision (benefit)

(90

)

 

(15

)

 

(7

)

 

(77

)

 

9

 

 

507

 

 

384

 

 

61

 

 

29

 

 

33

 

Certain Items attributable to Celanese Corporation (Table 8)

1,639

 

 

34

 

 

1,520

 

 

42

 

 

43

 

 

2,009

 

 

1,696

 

 

114

 

 

102

 

 

97

 

Adjusted EBIT

1,150

 

 

251

 

 

326

 

 

342

 

 

231

 

 

1,625

 

 

319

 

 

454

 

 

448

 

 

404

 

Depreciation and amortization expense(1)

743

 

 

184

 

 

191

 

 

188

 

 

180

 

 

728

 

 

184

 

 

187

 

 

181

 

 

176

 

Operating EBITDA

1,893

 

 

435

 

 

517

 

 

530

 

 

411

 

 

2,353

 

 

503

 

 

641

 

 

629

 

 

580

 

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions)

Engineered Materials

6

 

1

 

3

 

2

 

 

73

 

1

 

16

 

11

 

45

Acetyl Chain

11

 

11

 

 

 

 

 

 

 

 

Other Activities(2)

 

 

 

 

 

 

 

 

 

Accelerated depreciation and amortization expense

17

 

12

 

3

 

2

 

 

73

 

1

 

16

 

11

 

45

Depreciation and amortization expense(1)

743

 

184

 

191

 

188

 

180

 

728

 

184

 

187

 

181

 

176

Total depreciation and amortization expense

760

 

196

 

194

 

190

 

180

 

801

 

185

 

203

 

192

 

221

____________________

(1)

Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.

(2)

Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

Table 2

Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions, except percentages)

Operating Profit (Loss) / Operating Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

(958

)

 

(17.8

)%

 

111

 

 

8.7

%

 

(1,327

)

 

(95.9

)%

 

164

 

 

11.4

%

 

94

 

 

7.3

%

 

(1,197

)

 

(21.4

)%

 

(1,521

)

 

(119.9

)%

 

100

 

 

6.8

%

 

136

 

 

9.3

%

 

88

 

 

6.4

%

Acetyl Chain

539

 

 

12.7

%

 

90

 

 

9.6

%

 

135

 

 

12.7

%

 

153

 

 

13.7

%

 

161

 

 

14.4

%

 

946

 

 

19.9

%

 

215

 

 

19.4

%

 

238

 

 

20.0

%

 

241

 

 

20.0

%

 

252

 

 

20.0

%

Other Activities(1)

(367

)

 

 

 

(108

)

 

 

 

(83

)

 

 

 

(86

)

 

 

 

(90

)

 

 

 

(469

)

 

 

 

(113

)

 

 

 

(93

)

 

 

 

(130

)

 

 

 

(133

)

 

 

Total

(786

)

 

(8.2

)%

 

93

 

 

4.2

%

 

(1,275

)

 

(52.7

)%

 

231

 

 

9.1

%

 

165

 

 

6.9

%

 

(720

)

 

(7.0

)%

 

(1,419

)

 

(60.2

)%

 

245

 

 

9.3

%

 

247

 

 

9.3

%

 

207

 

 

7.9

%

Less: Net Earnings (Loss) Attributable to NCI for Engineered Materials

6

 

 

 

 

 

 

 

 

3

 

 

 

 

1

 

 

 

 

2

 

 

 

 

(1

)

 

 

 

2

 

 

 

 

2

 

 

 

 

(4

)

 

 

 

(1

)

 

 

Less: Net Earnings (Loss) Attributable to NCI for Acetyl Chain

8

 

 

 

 

3

 

 

 

 

1

 

 

 

 

2

 

 

 

 

2

 

 

 

 

9

 

 

 

 

1

 

 

 

 

2

 

 

 

 

2

 

 

 

 

4

 

 

 

Operating Profit (Loss) Attributable to Celanese Corporation

(800

)

 

(8.4

)%

 

90

 

 

4.1

%

 

(1,279

)

 

(52.9

)%

 

228

 

 

9.0

%

 

161

 

 

6.7

%

 

(728

)

 

(7.1

)%

 

(1,422

)

 

(60.3

)%

 

241

 

 

9.1

%

 

249

 

 

9.4

%

 

204

 

 

7.8

%

Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

(964

)

 

(17.9

)%

 

111

 

 

8.7

%

 

(1,330

)

 

(96.1

)%

 

163

 

 

11.3

%

 

92

 

 

7.1

%

 

(1,196

)

 

(21.4

)%

 

(1,523

)

 

(120.0

)%

 

98

 

 

6.6

%

 

140

 

 

9.5

%

 

89

 

 

6.5

%

Acetyl Chain

531

 

 

12.5

%

 

87

 

 

9.3

%

 

134

 

 

12.6

%

 

151

 

 

13.5

%

 

159

 

 

14.2

%

 

937

 

 

19.7

%

 

214

 

 

19.3

%

 

236

 

 

19.8

%

 

239

 

 

19.9

%

 

248

 

 

19.7

%

Other Activities(1)

(367

)

 

 

 

(108

)

 

 

 

(83

)

 

 

 

(86

)

 

 

 

(90

)

 

 

 

(469

)

 

 

 

(113

)

 

 

 

(93

)

 

 

 

(130

)

 

 

 

(133

)

 

 

Total

(800

)

 

(8.4

)%

 

90

 

 

4.1

%

 

(1,279

)

 

(52.9

)%

 

228

 

 

9.0

%

 

161

 

 

6.7

%

 

(728

)

 

(7.1

)%

 

(1,422

)

 

(60.3

)%

 

241

 

 

9.1

%

 

249

 

 

9.4

%

 

204

 

 

7.8

%

Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

109

 

 

 

 

32

 

 

 

 

35

 

 

 

 

25

 

 

 

 

17

 

 

 

 

178

 

 

 

 

33

 

 

 

 

46

 

 

 

 

49

 

 

 

 

50

 

 

 

Acetyl Chain

132

 

 

 

 

42

 

 

 

 

44

 

 

 

 

43

 

 

 

 

3

 

 

 

 

138

 

 

 

 

35

 

 

 

 

34

 

 

 

 

33

 

 

 

 

36

 

 

 

Other Activities(1)

15

 

 

 

 

3

 

 

 

 

4

 

 

 

 

3

 

 

 

 

5

 

 

 

 

48

 

 

 

 

4

 

 

 

 

16

 

 

 

 

13

 

 

 

 

15

 

 

 

Total

256

 

 

 

 

77

 

 

 

 

83

 

 

 

 

71

 

 

 

 

25

 

 

 

 

364

 

 

 

 

72

 

 

 

 

96

 

 

 

 

95

 

 

 

 

101

 

 

 

Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

3

 

 

 

 

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8

 

 

 

 

8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acetyl Chain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Activities(1)

52

 

 

 

 

47

 

 

 

 

2

 

 

 

 

1

 

 

 

 

2

 

 

 

 

(28

)

 

 

 

(35

)

 

 

 

3

 

 

 

 

2

 

 

 

 

2

 

 

 

Total

55

 

 

 

 

50

 

 

 

 

2

 

 

 

 

1

 

 

 

 

2

 

 

 

 

(20

)

 

 

 

(27

)

 

 

 

3

 

 

 

 

2

 

 

 

 

2

 

 

 

Certain Items Attributable to Celanese Corporation (Table 8)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

1,572

 

 

 

 

37

 

 

 

 

1,495

 

 

 

 

25

 

 

 

 

15

 

 

 

 

1,851

 

 

 

 

1,625

 

 

 

 

91

 

 

 

 

74

 

 

 

 

61

 

 

 

Acetyl Chain

32

 

 

 

 

17

 

 

 

 

9

 

 

 

 

1

 

 

 

 

5

 

 

 

 

22

 

 

 

 

3

 

 

 

 

5

 

 

 

 

4

 

 

 

 

10

 

 

 

Other Activities(1)

35

 

 

 

 

(20

)

 

 

 

16

 

 

 

 

16

 

 

 

 

23

 

 

 

 

136

 

 

 

 

68

 

 

 

 

18

 

 

 

 

24

 

 

 

 

26

 

 

 

Total

1,639

 

 

 

 

34

 

 

 

 

1,520

 

 

 

 

42

 

 

 

 

43

 

 

 

 

2,009

 

 

 

 

1,696

 

 

 

 

114

 

 

 

 

102

 

 

 

 

97

 

 

 

Adjusted EBIT / Adjusted EBIT Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

720

 

 

13.4

%

 

183

 

 

14.3

%

 

200

 

 

14.5

%

 

213

 

 

14.8

%

 

124

 

 

9.6

%

 

841

 

 

15.0

%

 

143

 

 

11.3

%

 

235

 

 

15.9

%

 

263

 

 

17.9

%

 

200

 

 

14.5

%

Acetyl Chain

695

 

 

16.4

%

 

146

 

 

15.5

%

 

187

 

 

17.6

%

 

195

 

 

17.5

%

 

167

 

 

15.0

%

 

1,097

 

 

23.0

%

 

252

 

 

22.7

%

 

275

 

 

23.1

%

 

276

 

 

23.0

%

 

294

 

 

23.3

%

Other Activities(1)

(265

)

 

 

 

(78

)

 

 

 

(61

)

 

 

 

(66

)

 

 

 

(60

)

 

 

 

(313

)

 

 

 

(76

)

 

 

 

(56

)

 

 

 

(91

)

 

 

 

(90

)

 

 

Total

1,150

 

 

12.0

%

 

251

 

 

11.4

%

 

326

 

 

13.5

%

 

342

 

 

13.5

%

 

231

 

 

9.7

%

 

1,625

 

 

15.8

%

 

319

 

 

13.5

%

 

454

 

 

17.1

%

 

448

 

 

16.9

%

 

404

 

 

15.5

%

____________________

(1)

Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

Table 2

Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions, except percentages)

Depreciation and Amortization Expense(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

441

 

 

 

 

105

 

 

 

 

115

 

 

 

 

112

 

 

 

 

109

 

 

 

 

437

 

 

 

 

114

 

 

 

 

111

 

 

 

 

110

 

 

 

 

102

 

 

 

Acetyl Chain

252

 

 

 

 

64

 

 

 

 

63

 

 

 

 

64

 

 

 

 

61

 

 

 

 

244

 

 

 

 

63

 

 

 

 

63

 

 

 

 

61

 

 

 

 

57

 

 

 

Other Activities(2)

50

 

 

 

 

15

 

 

 

 

13

 

 

 

 

12

 

 

 

 

10

 

 

 

 

47

 

 

 

 

7

 

 

 

 

13

 

 

 

 

10

 

 

 

 

17

 

 

 

Total

743

 

 

 

 

184

 

 

 

 

191

 

 

 

 

188

 

 

 

 

180

 

 

 

 

728

 

 

 

 

184

 

 

 

 

187

 

 

 

 

181

 

 

 

 

176

 

 

 

Operating EBITDA / Operating EBITDA Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

1,161

 

 

21.5

%

 

288

 

 

22.6

%

 

315

 

 

22.8

%

 

325

 

 

22.5

%

 

233

 

 

18.1

%

 

1,278

 

 

22.8

%

 

257

 

 

20.3

%

 

346

 

 

23.4

%

 

373

 

 

25.4

%

 

302

 

 

21.9

%

Acetyl Chain

947

 

 

22.4

%

 

210

 

 

22.3

%

 

250

 

 

23.6

%

 

259

 

 

23.2

%

 

228

 

 

20.4

%

 

1,341

 

 

28.2

%

 

315

 

 

28.4

%

 

338

 

 

28.4

%

 

337

 

 

28.0

%

 

351

 

 

27.8

%

Other Activities(2)

(215

)

 

 

 

(63

)

 

 

 

(48

)

 

 

 

(54

)

 

 

 

(50

)

 

 

 

(266

)

 

 

 

(69

)

 

 

 

(43

)

 

 

 

(81

)

 

 

 

(73

)

 

 

Total

1,893

 

 

19.8

%

 

435

 

 

19.7

%

 

517

 

 

21.4

%

 

530

 

 

20.9

%

 

411

 

 

17.2

%

 

2,353

 

 

22.9

%

 

503

 

 

21.3

%

 

641

 

 

24.2

%

 

629

 

 

23.7

%

 

580

 

 

22.2

%

____________________

(1)

Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See Table 1 for details.

(2)

Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

Table 3

Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

(In $ millions, except per share data)

Earnings (loss) from continuing operations attributable to Celanese Corporation

(1,144

)

 

(10.44

)

 

25

 

 

0.23

 

(1,357

)

 

(12.39

)

 

207

 

 

1.89

 

(19

)

 

(0.17

)

 

(1,534

)

 

(14.04

)

 

(1,920

)

 

(17.55

)

 

115

 

 

1.05

 

153

 

 

1.40

 

118

 

 

1.08

Income tax provision (benefit)

(90

)

 

 

 

(15

)

 

 

 

(7

)

 

 

 

(77

)

 

 

 

9

 

 

 

 

507

 

 

 

 

384

 

 

 

 

61

 

 

 

 

29

 

 

 

 

33

 

 

 

Earnings (loss) from continuing operations before tax

(1,234

)

 

 

 

10

 

 

 

 

(1,364

)

 

 

 

130

 

 

 

 

(10

)

 

 

 

(1,027

)

 

 

 

(1,536

)

 

 

 

176

 

 

 

 

182

 

 

 

 

151

 

 

 

Certain Items attributable to Celanese Corporation (Table 8)

1,639

 

 

 

 

34

 

 

 

 

1,520

 

 

 

 

42

 

 

 

 

43

 

 

 

 

2,009

 

 

 

 

1,696

 

 

 

 

114

 

 

 

 

102

 

 

 

 

97

 

 

 

Refinancing and related expenses

68

 

 

 

36

 

 

 

 

 

 

 

 

 

 

32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings (loss) from continuing operations before tax

473

 

 

 

 

80

 

 

 

 

156

 

 

 

 

172

 

 

 

 

65

 

 

 

 

982

 

 

 

 

160

 

 

 

 

290

 

 

 

 

284

 

 

 

 

248

 

 

 

Income tax (provision) benefit on adjusted earnings(1)

(36

)

 

 

 

(6

)

 

 

 

(9

)

 

 

 

(15

)

 

 

 

(6

)

 

 

 

(88

)

 

 

 

(14

)

 

 

 

(26

)

 

 

 

(26

)

 

 

 

(22

)

 

 

Adjusted earnings (loss) from continuing operations(2)

437

 

 

3.98

 

 

74

 

 

0.67

 

147

 

 

1.34

 

 

157

 

 

1.43

 

59

 

 

0.54

 

 

894

 

 

8.18

 

 

146

 

 

1.33

 

 

264

 

 

2.41

 

258

 

 

2.36

 

226

 

 

2.06

 

Diluted shares (in millions)(3)

Weighted average shares outstanding

109.5

 

 

 

 

109.6

 

 

 

 

109.6

 

 

 

 

109.5

 

 

 

 

109.4

 

 

 

 

109.3

 

 

 

 

109.4

 

 

 

 

109.3

 

 

 

 

109.3

 

 

 

 

109.1

 

 

 

Incremental shares attributable to equity awards

0.2

 

 

 

 

0.2

 

 

 

 

 

 

 

 

0.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

0.2

 

 

 

 

0.2

 

 

 

 

0.4

 

 

 

Total diluted shares

109.7

 

 

 

 

109.8

 

 

 

 

109.6

 

 

 

 

109.7

 

 

 

 

109.4

 

 

 

 

109.3

 

 

 

 

109.4

 

 

 

 

109.5

 

 

 

 

109.5

 

 

 

 

109.5

 

 

 

____________________

(1)

Calculated using adjusted effective tax rates (Table 3a) as follows:

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

 

Adjusted effective tax rate

8

 

 

 

8

 

 

 

6

 

 

 

9

 

 

 

9

 

 

 

9

 

 

 

9

 

 

 

9

 

 

 

9

 

 

 

9

 

 

 
(2)

Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.

 

 

Actual Plan Asset Returns

 

Expected

Plan Asset

Returns

 

 

(In percentages)

Q4 '25 & 2025

 

7.8

 

5.3

Q4 '24 & 2024

 

2.5

 

5.3

____________________
(3)

Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.

Table 3a

Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited

 

Actual

 

2025

 

2024

 

(In percentages)

U.S. GAAP annual effective tax rate

7

 

 

(50

)

Discrete quarterly recognition of GAAP items(1)

17

 

 

1

 

Tax impact of other charges and adjustments(2)

(12

)

 

98

 

Changes in valuation allowances, excluding impact of other charges and adjustments(3)

(12

)

 

(40

)

Other, includes effect of discrete current year transactions(4)

8

 

 

 

Adjusted tax rate

8

 

 

9

 

____________________
Note: As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate for actual results.

(1)

Such as changes in tax laws (including U.S. tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.

(2)

Reflects the tax impact on pre-tax adjustments presented in Certain Items (Table 8), which are excluded from pre-tax income for adjusted earnings per share purposes.

(3)

Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.

(4)

Includes tax impacts related to full-year actual tax opportunities and related costs, as well as current year realization of U.S. GAAP benefits deferred in prior years.

Table 4

Net Sales by Segment - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions)

Engineered Materials

5,390

 

 

1,277

 

 

1,384

 

 

1,442

 

 

1,287

 

 

5,595

 

 

1,269

 

 

1,481

 

 

1,467

 

 

1,378

 

Acetyl Chain

4,232

 

 

940

 

 

1,061

 

 

1,115

 

 

1,116

 

 

4,763

 

 

1,110

 

 

1,190

 

 

1,202

 

 

1,261

 

Intersegment eliminations(1)

(78

)

 

(13

)

 

(26

)

 

(25

)

 

(14

)

 

(90

)

 

(21

)

 

(23

)

 

(18

)

 

(28

)

Net sales

9,544

 

 

2,204

 

 

2,419

 

 

2,532

 

 

2,389

 

 

10,268

 

 

2,358

 

 

2,648

 

 

2,651

 

 

2,611

 

____________________

(1)

Includes intersegment sales primarily related to the Acetyl Chain.

Table 4a

Factors Affecting Segment Net Sales Sequentially - Unaudited

Three Months Ended December 31, 2025 Compared to Three Months Ended September 30, 2025

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(6

)

 

(2

)

 

 

(8

)

 

Acetyl Chain

(10

)

 

(1

)

 

 

(11

)

 

 

 

 

 

 

 

 

 

 

Total Company

(7

)

 

(2

)

 

 

(9

)

 

Three Months Ended September 30, 2025 Compared to Three Months Ended June 30, 2025

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(6

)

 

1

 

 

1

 

(4

)

 

Acetyl Chain

(2

)

 

(4

)

 

1

 

(5

)

 

 

 

 

 

 

 

 

 

 

Total Company

(4

)

 

(1

)

 

1

 

(4

)

 

Three Months Ended June 30, 2025 Compared to Three Months Ended March 31, 2025

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

9

 

 

 

 

3

 

12

 

Acetyl Chain

(1

)

 

(2

)

 

3

 

 

 

 

 

 

 

 

 

 

 

Total Company

4

 

 

(1

)

 

3

 

6

 

Three Months Ended March 31, 2025 Compared to Three Months Ended December 31, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

 

2

 

 

(1

)

 

1

 

Acetyl Chain

3

 

(1

)

 

(1

)

 

1

 

 

 

 

 

 

 

 

 

 

Total Company

2

 

 

 

(1

)

 

1

 

 

Three Months Ended December 31, 2024 Compared to Three Months Ended September 30, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(10

)

 

(3

)

 

(1

)

 

(14

)

 

Acetyl Chain

(4

)

 

(2

)

 

(1

)

 

(7

)

 

 

 

 

 

 

 

 

 

 

Total Company

(7

)

 

(3

)

 

(1

)

 

(11

)

 

Three Months Ended September 30, 2024 Compared to Three Months Ended June 30, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

 

 

 

1

 

1

 

 

Acetyl Chain

 

(2

)

 

1

 

(1

)

 

 

 

 

 

 

 

 

 

 

Total Company

 

(1

)

 

1

 

 

 

Three Months Ended June 30, 2024 Compared to Three Months Ended March 31, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

7

 

 

 

 

(1

)

 

6

 

 

Acetyl Chain

(1

)

 

(4

)

 

 

 

(5

)

 

 

 

 

 

 

 

 

 

 

Total Company

4

 

 

(2

)

 

 

 

2

 

 

Three Months Ended March 31, 2024 Compared to Three Months Ended December 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(1

)

 

 

 

(1

)

 

Acetyl Chain

5

 

 

1

 

1

 

7

 

 

 

 

 

 

 

 

 

 

 

Total Company

1

 

 

1

 

 

2

 

 

Table 4b

Factors Affecting Segment Net Sales Year Over Year - Unaudited

Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(2

)

 

 

 

3

 

1

 

 

Acetyl Chain

(10

)

 

(7

)

 

2

 

(15

)

 

 

 

 

 

 

 

 

 

 

Total Company

(6

)

 

(3

)

 

2

 

(7

)

 

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(8

)

 

(1

)

 

2

 

(7

)

 

Acetyl Chain

(4

)

 

(8

)

 

1

 

(11

)

 

 

 

 

 

 

 

 

 

 

Total Company

(6

)

 

(4

)

 

1

 

(9

)

 

Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(3

)

 

(1

)

 

2

 

(2

)

 

Acetyl Chain

(2

)

 

(7

)

 

2

 

(7

)

 

 

 

 

 

 

 

 

 

 

Total Company

(2

)

 

(4

)

 

2

 

(4

)

 

Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(4

)

 

(2

)

 

(1

)

 

(7

)

 

Acetyl Chain

(6

)

 

(4

)

 

(1

)

 

(11

)

 

 

 

 

 

 

 

 

 

 

Total Company

(5

)

 

(3

)

 

(1

)

 

(9

)

 

Three Months Ended December 31, 2024 Compared to Three Months Ended December 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(6

)

 

(3

)

 

 

(9

)

 

Acetyl Chain

(2

)

 

(4

)

 

 

(6

)

 

 

 

 

 

 

 

 

 

 

Total Company

(4

)

 

(4

)

 

 

(8

)

 

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(1

)

 

(2

)

 

 

(3

)

 

Acetyl Chain

1

 

 

(3

)

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

Total Company

 

 

(3

)

 

 

(3

)

 

Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(2

)

 

(4

)

 

(1

)

 

(7

)

 

Acetyl Chain

4

 

 

(6

)

 

(1

)

 

(3

)

 

 

 

 

 

 

 

 

 

 

Total Company

1

 

 

(5

)

 

(1

)

 

(5

)

 

Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(12

)

 

(2

)

 

(1

)

 

(15

)

 

Acetyl Chain

11

 

 

(10

)

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

Total Company

(2

)

 

(5

)

 

(1

)

 

(8

)

 

Table 4c

Factors Affecting Segment Net Sales Year Over Year - Unaudited

Year Ended December 31, 2025 Compared to Year Ended December 31, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(4

)

 

(1

)

 

1

 

(4

)

 

Acetyl Chain

(6

)

 

(6

)

 

1

 

(11

)

 

 

 

 

 

 

 

 

 

 

Total Company

(4

)

 

(4

)

 

1

 

(7

)

 

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(5

)

 

(3

)

 

(1

)

 

(9

)

 

Acetyl Chain

4

 

 

(6

)

 

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

Total Company

(1

)

 

(4

)

 

(1

)

 

(6

)

 

Table 5

Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions, except percentages)

Net cash provided by (used in) investing activities

(349

)

 

(104

)

 

(59

)

 

(88

)

 

(98

)

 

(470

)

 

(128

)

 

(100

)

 

(91

)

 

(151

)

Net cash provided by (used in) financing activities

(513

)

 

(324

)

 

(118

)

 

(116

)

 

45

 

 

(1,313

)

 

(189

)

 

(376

)

 

(489

)

 

(259

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) operating activities

1,146

 

 

252

 

 

447

 

 

410

 

 

37

 

 

966

 

 

494

 

 

79

 

 

292

 

 

101

 

Capital expenditures on property, plant and equipment

(343

)

 

(84

)

 

(64

)

 

(93

)

 

(102

)

 

(435

)

 

(105

)

 

(88

)

 

(105

)

 

(137

)

Contributions from/(Distributions) to NCI

(30

)

 

(8

)

 

(8

)

 

(6

)

 

(8

)

 

(33

)

 

(8

)

 

(7

)

 

(14

)

 

(4

)

Free cash flow(1)

773

 

 

160

 

 

375

 

 

311

 

 

(73

)

 

498

 

 

381

 

 

(16

)

 

173

 

 

(40

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

9,544

 

 

2,204

 

 

2,419

 

 

2,532

 

 

2,389

 

 

10,268

 

 

2,358

 

 

2,648

 

 

2,651

 

 

2,611

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Free cash flow as % of Net sales

8.1

%

 

7.3

%

 

15.5

%

 

12.3

%

 

(3.1

)%

 

4.9

%

 

16.2

%

 

(0.6

)%

 

6.5

%

 

(1.5

)%

____________________

(1)

Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures.

Table 6

Cash Dividends Received - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions)

Dividends from equity method investments

139

 

47

 

40

 

21

 

31

 

160

 

38

 

26

 

69

 

27

Dividends from equity investments without readily determinable fair values

122

 

40

 

40

 

41

 

1

 

128

 

33

 

30

 

31

 

34

Total

261

 

87

 

80

 

62

 

32

 

288

 

71

 

56

 

100

 

61

Table 7

Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

(In $ millions)

Short-term borrowings and current installments of long-term debt - third party and affiliates

1,204

 

 

1,204

 

 

1,199

 

 

252

 

 

406

 

 

1,501

 

 

1,501

 

 

1,607

 

 

1,977

 

 

2,439

 

Long-term debt, net of unamortized deferred financing costs

11,394

 

 

11,394

 

 

11,655

 

 

12,689

 

 

12,378

 

 

11,078

 

 

11,078

 

 

11,324

 

 

11,058

 

 

11,018

 

Total debt

12,598

 

 

12,598

 

 

12,854

 

 

12,941

 

 

12,784

 

 

12,579

 

 

12,579

 

 

12,931

 

 

13,035

 

 

13,457

 

Cash and cash equivalents

(1,263

)

 

(1,263

)

 

(1,440

)

 

(1,173

)

 

(951

)

 

(962

)

 

(962

)

 

(813

)

 

(1,185

)

 

(1,483

)

Net debt

11,335

 

 

11,335

 

 

11,414

 

 

11,768

 

 

11,833

 

 

11,617

 

 

11,617

 

 

12,118

 

 

11,850

 

 

11,974

 

Table 8

Certain Items - Unaudited

The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:

 

2025

 

Q4 '25

 

Q3 '25

 

Q2 '25

 

Q1 '25

 

2024

 

Q4 '24

 

Q3 '24

 

Q2 '24

 

Q1 '24

 

Income Statement Classification

 

(In $ millions)

 

 

Exit and shutdown costs

98

 

 

29

 

 

10

 

27

 

32

 

236

 

47

 

52

 

69

 

68

 

 

Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net / Non-operating pension and other postretirement employee benefit (expense) income

Asset impairments

1,513

 

 

27

 

(1)

1,486

(2)

 

 

1,638

 

1,601

(3)

34

(4)

3

 

 

 

Cost of sales / Other (charges) gains, net

Impact from plant incidents and natural disasters

3

 

 

 

 

 

 

3

 

13

 

3

 

3

 

 

7

 

 

Cost of sales

Mergers, acquisitions and dispositions

52

 

 

23

 

 

12

 

12

 

5

 

80

 

12

 

17

 

26

 

25

 

 

Cost of sales / SG&A

Actuarial (gain) loss on pension and postretirement plans

(49

)

 

(49

)

 

 

 

 

27

 

27

 

 

 

 

 

Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income

Legal settlements and commercial disputes

17

 

 

1

 

 

11

 

2

 

3

 

8

 

6

 

7

 

3

 

(8

)

 

Cost of sales / SG&A / Other (charges) gains, net

(Gain) loss on disposition of businesses and assets

 

 

 

 

 

 

 

2

 

 

1

 

1

 

 

 

Gain (loss) on disposition of businesses and assets, net

Other

5

 

 

3

 

 

1

 

1

 

 

5

 

 

 

 

5

 

 

Cost of sales / SG&A

Certain Items attributable to Celanese Corporation

1,639

 

 

34

 

 

1,520

 

42

 

43

 

2,009

 

1,696

 

114

 

102

 

97

 

 

 

____________________

(1)

Related to impairment of certain long-lived assets arising from unused parcels of property subsequently sold.

(2)

Related to impairment of goodwill and certain trade names, primarily Zytel®, arising from our annual goodwill and indefinite-lived intangible assets impairment tests.

(3)

Related to impairment of goodwill and certain trade names, primarily Zytel®, arising from our interim goodwill and indefinite-lived intangible assets impairment tests.

(4)

Related to impairment of certain trade names, primarily Zytel®, in connection with our annual goodwill and indefinite-lived intangible asset impairment tests.

Table 9

Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited

 

 

 

 

 

2025

 

 

 

 

 

2024

 

 

 

 

 

(In $ millions, except percentages)

 

 

 

 

 

(In $ millions, except percentages)

Net earnings (loss) attributable to Celanese Corporation

 

 

 

 

(1,165

)

 

 

 

 

 

(1,542

)

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBIT (Table 1)

 

 

 

 

1,150

 

 

 

 

 

 

1,625

 

Adjusted effective tax rate (Table 3a)

 

 

 

 

8

%

 

 

 

 

 

9

%

Adjusted EBIT tax effected

 

 

 

 

1,058

 

 

 

 

 

 

1,479

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

2024

 

Average

 

2024

 

2023

 

Average

 

(In $ millions, except percentages)

Short-term borrowings and current installments of long-term debt - third parties and affiliates

1,204

 

1,501

 

1,353

 

 

1,501

 

1,383

 

1,442

 

Long-term debt, net of unamortized deferred financing costs

11,394

 

11,078

 

11,236

 

 

11,078

 

12,301

 

11,690

 

Celanese Corporation shareholders' equity

4,049

 

5,129

 

4,589

 

 

5,129

 

7,065

 

6,097

 

Invested capital

 

 

 

 

17,178

 

 

 

 

 

 

19,229

 

 

 

 

 

 

 

 

 

 

 

 

 

Return on invested capital (adjusted)

 

 

 

 

6.2

%

 

 

 

 

 

7.7

%

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital

 

 

 

 

(6.8

)%

 

 

 

 

 

(8.0

)%

 

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  201.15
+2.36 (1.19%)
AAPL  263.88
+8.10 (3.17%)
AMD  203.08
-4.24 (-2.05%)
BAC  52.74
+0.19 (0.36%)
GOOG  302.82
-3.20 (-1.05%)
META  639.29
-0.48 (-0.08%)
MSFT  396.86
-4.46 (-1.11%)
NVDA  184.97
+2.16 (1.18%)
ORCL  153.97
-6.17 (-3.85%)
TSLA  410.63
-6.81 (-1.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.